OBJECTIVE: Observational studies show that when a depressed mother's symptoms remit, her children's psychiatric symptoms decrease. Using randomized treatment assignment, the authors sought to determine the differential effects of a depressed mother's treatment on her child. METHOD: The study was a randomized double-blind 12-week trial of escitalopram, bupropion, or the combination of the two in depressed mothers (N=76), with independent assessment of their children (N=135; ages 7-17 years). RESULTS: There were no significant treatment differences in mothers' depressive symptoms or remission. Children's depressive symptoms and functioning improved significantly among those whose mothers were in the escitalopram group (compared with those whose mothers were in the bupropion and combination treatment groups). Only in the escitalopram group was significant improvement of mother's depression associated with improvement in the child's symptoms. Exploratory analyses suggested that this may be due to changes in parental functioning: Mothers in the escitalopram group reported significantly greater improvement, compared with the other groups, in their ability to listen and talk to their children, who as a group reported that their mothers were more caring over the 12 weeks. Maternal baseline negative affectivity appeared to moderate the effect of maternal treatment on children, although the effect was not statistically significant. Children of mothers with low negative affectivity improved in all treatment groups. Children of mothers withhigh negative affectivity improved significantly only for those whose mothers were in the escitalopram group. CONCLUSIONS: The effects of the depressed mother's improvement on her children may depend on her type of treatment. Depressed mothers with high anxious distress and irritability may require medications that reduce these symptoms in order to show the effect of her remission on her children.
RCT Entities:
OBJECTIVE: Observational studies show that when a depressed mother's symptoms remit, her children's psychiatric symptoms decrease. Using randomized treatment assignment, the authors sought to determine the differential effects of a depressed mother's treatment on her child. METHOD: The study was a randomized double-blind 12-week trial of escitalopram, bupropion, or the combination of the two in depressed mothers (N=76), with independent assessment of their children (N=135; ages 7-17 years). RESULTS: There were no significant treatment differences in mothers' depressive symptoms or remission. Children's depressive symptoms and functioning improved significantly among those whose mothers were in the escitalopram group (compared with those whose mothers were in the bupropion and combination treatment groups). Only in the escitalopram group was significant improvement of mother's depression associated with improvement in the child's symptoms. Exploratory analyses suggested that this may be due to changes in parental functioning: Mothers in the escitalopram group reported significantly greater improvement, compared with the other groups, in their ability to listen and talk to their children, who as a group reported that their mothers were more caring over the 12 weeks. Maternal baseline negative affectivity appeared to moderate the effect of maternal treatment on children, although the effect was not statistically significant. Children of mothers with low negative affectivity improved in all treatment groups. Children of mothers with high negative affectivity improved significantly only for those whose mothers were in the escitalopram group. CONCLUSIONS: The effects of the depressed mother's improvement on her children may depend on her type of treatment. Depressed mothers with high anxious distress and irritability may require medications that reduce these symptoms in order to show the effect of her remission on her children.
Authors: David Nutt; Koen Demyttenaere; Zoltan Janka; Trond Aarre; Michel Bourin; Pier Luigi Canonico; Jose Luis Carrasco; Steven Stahl Journal: J Psychopharmacol Date: 2006-10-18 Impact factor: 4.153
Authors: Myrna M Weissman; Priya Wickramaratne; Yoko Nomura; Virginia Warner; Helen Verdeli; Daniel J Pilowsky; Christian Grillon; Gerard Bruder Journal: Arch Gen Psychiatry Date: 2005-01
Authors: George I Papakostas; Stephen M Stahl; Alok Krishen; Cheryl A Seifert; Vivian L Tucker; Elizabeth P Goodale; Maurizio Fava Journal: J Clin Psychiatry Date: 2008-08 Impact factor: 4.384
Authors: Myrna M Weissman; Adriana Feder; Daniel J Pilowsky; Mark Olfson; Milton Fuentes; Carlos Blanco; Rafael Lantigua; Marc J Gameroff; Steven Shea Journal: J Affect Disord Date: 2004-02 Impact factor: 4.839
Authors: Daniel J Pilowsky; Priya Wickramaratne; Ardesheer Talati; Min Tang; Carroll W Hughes; Judy Garber; Erin Malloy; Cheryl King; Gabrielle Cerda; A Bela Sood; Jonathan E Alpert; Madhukar H Trivedi; Maurizio Fava; A John Rush; Stephen Wisniewski; Myrna M Weissman Journal: Am J Psychiatry Date: 2008-06-16 Impact factor: 18.112
Authors: Joan L Luby; Deanna M Barch; Diana Whalen; Rebecca Tillman; Kenneth E Freedland Journal: Am J Psychiatry Date: 2018-06-20 Impact factor: 18.112
Authors: Holly A Swartz; Jill M Cyranowski; Yu Cheng; Allan Zuckoff; David A Brent; John C Markowitz; Stacy Martin; Marlissa C Amole; Fiona Ritchey; Ellen Frank Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-04-07 Impact factor: 8.829
Authors: Judith K Morgan; Marigrace Ambrosia; Erika E Forbes; Jill M Cyranowski; Marlissa C Amole; Jennifer S Silk; Rosalind D Elliott; Holly A Swartz Journal: J Affect Disord Date: 2015-08-24 Impact factor: 4.839